Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Expenditures (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Capital Expenditures for 7 consecutive years, with $11.8 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 2986.16% to $11.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.9 million through Dec 2025, up 1692.09% year-over-year, with the annual reading at $14.9 million for FY2025, 1692.09% up from the prior year.
  • Capital Expenditures for Q4 2025 was $11.8 million at Beam Therapeutics, up from -$3.1 million in the prior quarter.
  • The five-year high for Capital Expenditures was $43.3 million in Q4 2022, with the low at -$5.0 million in Q2 2023.
  • Average Capital Expenditures over 5 years is $7.3 million, with a median of $3.6 million recorded in 2024.
  • The sharpest move saw Capital Expenditures skyrocketed 5778.6% in 2021, then crashed 4292.86% in 2025.
  • Over 5 years, Capital Expenditures stood at $13.4 million in 2021, then soared by 223.83% to $43.3 million in 2022, then dropped by 27.15% to $31.5 million in 2023, then plummeted by 98.79% to $383000.0 in 2024, then skyrocketed by 2986.16% to $11.8 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $11.8 million, -$3.1 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.